Sanofi Stock Revenue
| SNYNF Stock | USD 105.85 0.50 0.47% |
Sanofi fundamentals help investors to digest information that contributes to Sanofi's financial success or failures. It also enables traders to predict the movement of Sanofi Pink Sheet. The fundamental analysis module provides a way to measure Sanofi's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanofi pink sheet.
Sanofi |
Sanofi Company Revenue Analysis
Sanofi's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Sanofi Revenue | 45.39 B |
Most of Sanofi's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Sanofi reported 45.39 B of revenue. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The revenue for all United States stocks is significantly lower than that of the firm.
Sanofi Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sanofi could also be used in its relative valuation, which is a method of valuing Sanofi by comparing valuation metrics of similar companies.Sanofi is currently under evaluation in revenue category among its peers.
Sanofi Fundamentals
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 135.37 B | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Insiders | 11.23 % | |||
| Shares Owned By Institutions | 46.69 % | |||
| Price To Earning | 7.73 X | |||
| Price To Book | 1.60 X | |||
| Price To Sales | 2.73 X | |||
| Revenue | 45.39 B | |||
| Gross Profit | 31.69 B | |||
| EBITDA | 10.76 B | |||
| Net Income | 6.72 B | |||
| Cash And Equivalents | 6.9 B | |||
| Cash Per Share | 5.51 X | |||
| Total Debt | 14.86 B | |||
| Debt To Equity | 0.30 % | |||
| Current Ratio | 1.30 X | |||
| Book Value Per Share | 58.33 X | |||
| Cash Flow From Operations | 10.52 B | |||
| Earnings Per Share | 5.77 X | |||
| Price To Earnings To Growth | 1.63 X | |||
| Target Price | 123.28 | |||
| Number Of Employees | 58 | |||
| Beta | 0.41 | |||
| Market Capitalization | 120.25 B | |||
| Total Asset | 124.58 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.83 % | |||
| Net Asset | 124.58 B | |||
| Last Dividend Paid | 3.56 |
About Sanofi Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanofi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sanofi Pink Sheet
Sanofi financial ratios help investors to determine whether Sanofi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sanofi with respect to the benefits of owning Sanofi security.